Hematopoiesis News 7.21 May 31, 2016 | |
| |
TOP STORYInvestigators measured, at the clonal level, repopulating waves, populations’ sizes and dynamics, activity of distinct hematopoietic stem/progenitor cells subtypes, contribution of various progenitor classes during the early and late post-transplant phases, and hierarchical relationships among lineages. [Cell Stem Cell] Full Article | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CXCR2 and CXCL4 Regulate Survival and Self-Renewal of Hematopoietic Stem/Progenitor Cells The authors investigated global transcriptomic profiling of normal human hematopoietic stem/progenitor cells, revealing that several chemokine ligands (CXCL1-4, CXCL6, CXCL10, CXCL11, CXCL13) were up-regulated in human quiescent CD34+Hoescht–Pyronin Y– and primitive CD34+38–, as compared to proliferating CD34+Hoechst+Pyronin Y+ and CD34+38+ stem/progenitor cells. [Blood] Abstract The authors demonstrated that hemogenic competency in recently specified endothelial progenitors is restrained through the active silencing of Runx1 expression. [Cell Rep] Full Article | Graphical Abstract Scientists showed that Morc3 is a previously unreported regulator of cortical bone homeostasis and hematopoietic stem cells niche, accompanied by altered bone cell differentiation. [Sci Rep] Abstract Since Ly6aGFP is a marker of all hematopoietic stem cells (HSCs), some hematopoietic cluster cells and hemogenic endothelial cells in the midgestation mouse aorta, researchers examined whether embryonic head HSCs and vascular endothelial cells are positive for this marker. [Dev Biol] Abstract Investigators used whole-mount immunostaining and 3D confocal reconstruction techniques to analyze both c-Kit+ hematopoietic clusters and Runx1+ hemogenic endothelium in the whole-head vasculature. [PLoS One] Abstract Investigators hypothesized that older women demonstrating clonal hematopoiesis, defined here as a functional phenomenon in which a hematopoietic stem cell has acquired a survival and proliferative advantage, harbor a higher frequency of somatic mutations in chromatin and epigenetic regulatory genes. [Exp Hematol] Abstract CLINICAL RESEARCHScientists retrospectively analyzed 95 patients, 85 with multiple myeloma and 10 with plasma cell leukemia, receiving single or double umbilical cord blood transplantation from 2001 to 2013. [Haematologica] Abstract Twenty-five adult T-cell leukemia/lymphoma patients were treated with mogamulizumab before allo-hematopoietic stem cell transplantation, after which 18 patients (72%) achieved remission. [Biol Blood Marrow Transplant] Abstract | |
| |
REVIEWSHematopoiesis during Development, Aging and Disease Researchers describe how the different phases that comprise birth, maintenance, functional decline, derailment, and death of hematopoietic stem cell, are continuous processes that may all be controlled by Polycomb group proteins. [Exp Hematol] Abstract Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
| |
INDUSTRY NEWSMundipharma EDO GmbH Announces First-in-human Clinical Trial of its Lead Compound, EDO-S101 Mundipharma EDO GmbH (Early Development in Oncology) has announced the initiation of a first-in-human clinical trial of its investigational drug candidate EDO-S101. A first in class, fusion molecule – S101 is currently being developed for the treatment of relapsed-refractory hematological malignances. [Mundipharma EDO GmbH] Press Release AbbVie announced that the European Commission (EC) approved IMBRUVICA® as a first-line treatment option for adult patients with chronic lymphocytic leukemia (CLL), expanding upon the initial EC approval in October 2014 for certain patients with CLL. [Abbvie] Press Release Syros Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) accepted the company’s investigational new drug application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha agonist, into a Phase II clinical trial in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome identified through its platform [Syros Pharmaceuticals] Press Release | |
From our sponsor: Working with blood? Download the immune cell frequencies app.
| |
EVENTSNEW Gordon Research Conference – Notch Signaling in Development, Regeneration & Disease Visit our events page to see a complete list of events in the hematopoiesis community.
| |
JOB OPPORTUNITIESNEW Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center) NEW Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Novartis) Scientific Communications and Publishing Coordinator (STEMCELL Technologies Inc.) Technical Sales Representative (STEMCELL Technologies Inc.) Scientist – Hematology (STEMCELL Technologies Inc.) Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London) Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University) Postdoctoral Fellow – Leukemia Lymphoma (Emory University) Postdoctoral Scientist – Mouse Hematopoiesis (Lund University) Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center) Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California) Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania) Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hematopoiesis News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Hematopoiesis News Volume 7.21 | May 31 2016